Clinical Trial Update: Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors [EARLY_Phase 1]

View source ↗

Summary

Early-phase trial assessing serologic response to SHINGRIX in patients with CLL or WM treated with BTK inhibitors; completed with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Waldenstrom Macroglobulinemia

Drugs mentioned

• Shingrix (recombinant zoster vaccine, adjuvanted)

Snippet

Sponsor: University of Rochester | Conditions: Chronic Lymphocytic Leukemia (CLL), Waldenstrom Macroglobulinemia (WM) | EARLY_Phase 1 | Status: COMPLETED | Results posted: 2024-01-22